Hyloris secures a €6 million non-dilutive financing package to support portfolio expansion and licensing negotiations. The funding provides financial flexibility for advancing strategic discussions without issuing additional equity. The company aims to leverage the liquidity buffer for future growth initiatives.
Hyloris Pharmaceuticals encounters an FDA manufacturing delay for its **Valacyclovir** drug product. The setback involves regulatory scrutiny of its production processes, potentially impacting approval timelines. The company develops generic antiviral medications targeting unmet patient needs.
Hyloris secures FDA acceptance of its New Drug Application (NDA) for a new valacyclovir formulation. The company also announces three new partnerships this month, expanding its development pipeline. The filings mark a key milestone for Hyloris’ value-added medicines portfolio.
Hyloris Pharmaceuticals secures FDA approval for its non-opioid drug designed to treat post-operative pain. The Belgium-based company plans to launch the treatment in the United States within the first quarter of 2024. The approval marks a significant step for the company’s pain management solutions.
Oct 2023Yahoo FinanceNews article
Hyloris Pharmaceuticals
Hyloris Pharmaceuticals is a specialty pharma firm developing products via the 505(b)(2) route for drugs with established safety and efficacy.
